Cover Image
市場調查報告書

Wellstat Therapeutics Corporation:產品平台分析

Wellstat Therapeutics Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 224737
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Wellstat Therapeutics Corporation:產品平台分析 Wellstat Therapeutics Corporation - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 24 Pages
簡介

Wellstat Therapeutics Corporation是從事癌症治療藥的開發,商品化的生物醫藥品企業。

本報告提供Wellstat Therapeutics Corporation的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Wellstat Therapeutics Corporation的基本資料

Wellstat Therapeutics Corporation概要

  • 主要資訊
  • 企業資料

Wellstat Therapeutics Corporation:R&D概要

  • 主要的治療範圍

Wellstat Therapeutics Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Wellstat Therapeutics Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Wellstat Therapeutics Corporation:藥物簡介

  • uridine triacetate
  • PN-2XXX
  • PN-951
  • PN-XXXX

Wellstat Therapeutics Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Wellstat Therapeutics Corporation:最近的開發平台趨勢

Wellstat Therapeutics Corporation:暫停中的計劃

Wellstat Therapeutics Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04926CDB

Global Markets Direct's, 'Wellstat Therapeutics Corporation - Product Pipeline Review - 2014', provides an overview of the Wellstat Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Wellstat Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Wellstat Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Wellstat Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Wellstat Therapeutics Corporation's pipeline products

Reasons to buy

  • Evaluate Wellstat Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Wellstat Therapeutics Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Wellstat Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Wellstat Therapeutics Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Wellstat Therapeutics Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Wellstat Therapeutics Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Wellstat Therapeutics Corporation Snapshot
    • Wellstat Therapeutics Corporation Overview
    • Key Information
    • Key Facts
  • Wellstat Therapeutics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Wellstat Therapeutics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Wellstat Therapeutics Corporation - Pipeline Products Glance
    • Wellstat Therapeutics Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Wellstat Therapeutics Corporation - Early Stage Pipeline Products
    • Preclinical Products/Combination Treatment Modalities
  • Wellstat Therapeutics Corporation - Drug Profiles
    • uridine triacetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PN-2XXX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PN-951
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PN-XXXX
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Wellstat Therapeutics Corporation - Pipeline Analysis
    • Wellstat Therapeutics Corporation - Pipeline Products by Target
    • Wellstat Therapeutics Corporation - Pipeline Products by Route of Administration
    • Wellstat Therapeutics Corporation - Pipeline Products by Molecule Type
    • Wellstat Therapeutics Corporation - Pipeline Products by Mechanism of Action
  • Wellstat Therapeutics Corporation - Recent Pipeline Updates
  • Wellstat Therapeutics Corporation - Dormant Projects
  • Wellstat Therapeutics Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Wellstat Therapeutics Corporation, Key Information
  • Wellstat Therapeutics Corporation, Key Facts
  • Wellstat Therapeutics Corporation - Pipeline by Indication, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Stage of Development, 2014
  • Wellstat Therapeutics Corporation - Monotherapy Products in Pipeline, 2014
  • Wellstat Therapeutics Corporation - Phase II, 2014
  • Wellstat Therapeutics Corporation - Preclinical, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Target, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Route of Administration, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Molecule Type, 2014
  • Wellstat Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2014
  • Wellstat Therapeutics Corporation - Recent Pipeline Updates, 2014
  • Wellstat Therapeutics Corporation - Dormant Developmental Projects,2014

List of Figures

  • Wellstat Therapeutics Corporation - Pipeline by Top 10 Indication, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Stage of Development, 2014
  • Wellstat Therapeutics Corporation - Monotherapy Products in Pipeline, 2014
  • Wellstat Therapeutics Corporation - Pipeline by Top 10 Molecule Type, 2014
Back to Top